JBC117, a novel anticancer lead compound targeting Pygo2 PHD, effectively antagonizes β-catenin-dependent cell activity, inhibits cancer cell migration and invasion, and induces apoptosis [1].

JBC117 at a concentration of 20 μM over 24 hours inhibits the growth of colon cancer (HCT116) and lung cancer (A549) cells, with IC50 values of 2.6 and 3.3 μM respectively [1]. Western Blot Analysis on HCT116 and A549 cell lines treated with 5, 10, and 20 μM for 72 hours demonstrates downregulation of Wnt downstream target genes, including Axin2, c-myc, and cyclin D1. Furthermore, in Cell Invasion Assays, HCT116 and A549 cells treated with 20 μM for 24 hours showed dose-dependent reductions in migration and invasion capabilities.

JBC117, administered at 20 mg/kg per day subcutaneously for 14 consecutive days, demonstrates antitumor activity in mouse xenograft models of colon and lung cancer [1]. Results showed a reduction in tumor growth by 65% in colon cancer and 93% in lung cancer, with increased apoptosis observed in tumor sections.